ARAV News and Press, Aravive Inc. From 02/23/23

If you’re looking for penny stocks to buy, you might want to get a second opinion. You could go to places like Fintwit or Reddit to discover what the mom-and-pop investors are speculating on. Another way to see varying perceptions of companies is to find out what analysts think. Using ...

HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 1b/2 trial of batir...

Topline data expected mid-2023 Potential Biologics License Application (BLA) submission end of 2023 HOUSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to treat me...

Summary Aravive shareholders have been heavily diluted and suffered substantial losses in 2022. The company has struggled for cash, but now says it has funds to last at least until a pivotal data readout in 2023 for lead and only candidate Batiraxcept. Earlier data has offered encou...

FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group –  A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this week, causing a flurry...

HOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Desig...

HOUSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer wil...

HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt of a formal notification from the Staff at The Nasdaq S...

Continued Advancement of Clinical Trials in Platinum Resistant Ovarian Cancer (PROC), Clear Cell Renal Cell Carcinoma and Pancreatic Adenocarcinoma Secured Funding to Take the Company Beyond the PROC Readout in Mid-2023 Advanced Development of Batiraxcept in Ch...

More Short Squeeze Penny Stocks For Your November Watch List If you want to make money with penny stocks, learning how to find them and what to look for is a great first step. This article looks at a phenomenon known as a short squeeze. In this scenario, traders will bet against stocks ...